改变生活方式可以逆转冠心病吗? 生活方式的心脏试验
D Ornish1, S E Brown, L W Scherwitz
1Pacific Presbyterian Medical Center, Sausalito, California.
Lancet (London, England)
|July 21, 1990
概括
在一项为期一年的研究中,包括饮食和运动在内的全面的生活方式改变显著减少了冠状动脉样硬化. 这种方法表明,即使在没有药物治疗的情况下,即使是严重的动脉阻塞也会回归.
科学领域:
- 心脏病学 心脏病学
- 预防医学 预防医学
- 营养科学 营养科学
背景情况:
- 冠状动脉样硬化是全球死亡的主要原因.
- 传统的治疗通常集中在降脂药物上,在逆转已有的疾病方面取得的成功有限.
- 综合生活方式干预对动脉硬性斑块回归的潜在影响需要进一步调查.
研究的目的:
- 评估全面的生活方式干预对冠状动脉样硬化进展的影响.
- 为了确定冠状动脉病变的显著回归是否可以在一年内实现.
- 评估非药理学方法在治疗冠状动脉疾病中的有效性.
主要方法:
- 一项前性随机对照试验与48名患者进行.
- 实验组 (28名患者) 采用低脂肪素食饮食,戒烟,压力管理和适度运动.
- 对照组 (20名患者) 接受了通常的护理.
- 定量冠状动脉血管学用于分析195个冠状动脉病变在1年之前和之后.
主要成果:
- 实验组显示,平均百分比直径狭窄症的回归率从40.0%降至37.8%.
- 对照组经历了进展,平均百分比直径狭窄症从42.7%增加到46.1%.
- 在严重的病变 (>50%狭窄) 中,实验组的回归率从61.1%降至55.8%,而对照组的进展率从61.7%降至64.4%.
- 实验组中82%的患者表现出冠状动脉样硬化的回归.
结论:
- 全面改变生活方式可以在一年内诱导冠状动脉样硬化的回归,包括严重的病例.
- 这种干预为治疗冠状动脉疾病提供了一个潜在的非药物战略.
- 需要进一步的研究来探索长期影响和更广泛的适用性.
相关概念视频
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


